-
公开(公告)号：US09168245B2
公开(公告)日：2015-10-27
申请号：US14234935
申请日：2012-07-24
申请人： Abdellah Benjahad , Alain Moussy , Emmanuel Chevenier , Willy Picoul , Anne Lermet , Didier Pez , Jason Martin , Franck Sandrinelli
发明人： Abdellah Benjahad , Alain Moussy , Emmanuel Chevenier , Willy Picoul , Anne Lermet , Didier Pez , Jason Martin , Franck Sandrinelli
IPC分类号： C07D413/14 , C07D417/14 , C07D413/10 , C07D417/10 , A61K31/535 , A61K31/42 , A61K31/445 , A61K31/497 , A61K31/505 , A61K31/422 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377
CPC分类号： A61K31/422 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14
摘要： The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐：其中R1，R2，R3，A，Q，W和X如说明书中所定义。 这些化合物选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，变态反应和退行性疾病的某些天然和/或突变蛋白激酶介导的信号转导。 更具体地说，这些化合物是有效和选择性的天然和/或突变c-kit抑制剂。
-
公开(公告)号：US20140179698A1
公开(公告)日：2014-06-26
申请号：US14234935
申请日：2012-07-24
申请人： Abdellah Benjahad , Alain Moussy , Emmanuel Chevenier , Willy Picoul , Anne Lermet , Didier Pez , Jason Martin , Franck Sandrinelli
发明人： Abdellah Benjahad , Alain Moussy , Emmanuel Chevenier , Willy Picoul , Anne Lermet , Didier Pez , Jason Martin , Franck Sandrinelli
IPC分类号： C07D413/14 , A61K31/422 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/506 , C07D413/10 , A61K31/454
CPC分类号： A61K31/422 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14
摘要： The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description.These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐：其中R1，R2，R3，A，Q，W和X如说明书中所定义。 这些化合物选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，变态反应和退行性疾病的某些天然和/或突变蛋白激酶介导的信号转导。 更具体地说，这些化合物是有效和选择性的天然和/或突变c-kit抑制剂。
-
公开(公告)号：US08962665B2
公开(公告)日：2015-02-24
申请号：US13521676
申请日：2011-01-12
申请人： Alain Moussy , Abdellah Benjahad , Jason Martin , Emmanuel Chevenier , Didier Pez , Franck Sandrinelli , Willy Picoul
发明人： Alain Moussy , Abdellah Benjahad , Jason Martin , Emmanuel Chevenier , Didier Pez , Franck Sandrinelli , Willy Picoul
IPC分类号： A61K31/42 , C07D413/00 , C07D413/14 , C07D413/12 , C07D417/14
CPC分类号： C07D413/14 , C07D413/12 , C07D417/14
摘要： The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
摘要翻译： 本发明涉及选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，过敏和 退行性疾病 特别地，这些化合物中的几种是有效的和选择性的Flt-3抑制剂或/和syk抑制剂。
-
公开(公告)号：US20130035331A1
公开(公告)日：2013-02-07
申请号：US13521676
申请日：2011-01-12
申请人： Alain Moussy , Abdellah Benjahad , Jason Martin , Emmanuel Chevenier , Didier Pez , Franck Sandrinelli , Willy Picoul
发明人： Alain Moussy , Abdellah Benjahad , Jason Martin , Emmanuel Chevenier , Didier Pez , Franck Sandrinelli , Willy Picoul
IPC分类号： A61K31/444 , C07D413/12 , A61K31/4439 , A61P17/00 , C07D417/14 , A61K31/541 , A61P35/00 , A61P37/00 , C07D413/14 , A61K31/5377
CPC分类号： C07D413/14 , C07D413/12 , C07D417/14
摘要： The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
摘要翻译： 本发明涉及选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，过敏和 退行性疾病 特别地，这些化合物中的几种是有效的和选择性的Flt-3抑制剂或/和syk抑制剂。
-
5.发明申请Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors 审中-公开取代的恶唑衍生物及其作为酪氨酸激酶抑制剂的用途公开(公告)号：US20080242704A1
公开(公告)日：2008-10-02
申请号：US11910497
申请日：2006-04-04
IPC分类号： A61K31/4439 , C07D413/04 , C07D413/12 , A61K31/423 , A61K31/422 , A61P29/00 , A61P37/00 , A61P35/00 , C07D413/14
CPC分类号： C07D263/48 , C07D263/46 , C07D263/58 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Fit-3 inhibitors.
摘要翻译： 本发明涉及选自式（I）的取代的恶唑衍生物的新化合物，其选择性调节，调节和/或抑制由涉及各种人和动物疾病的某些天然和/或突变型酪氨酸激酶介导的信号转导，例如 细胞增殖，代谢，过敏和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl和Fit-3抑制剂。
-
6.发明授权Substituted oxazole derivatives and their use as tyrosine kinase inhibitors 有权取代的恶唑衍生物及其作为酪氨酸激酶抑制剂的用途公开(公告)号：US08658659B2
公开(公告)日：2014-02-25
申请号：US13343968
申请日：2012-01-05
IPC分类号： C07D263/46 , C07D263/58 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D263/48 , C07D263/46 , C07D263/58 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Flt-3 inhibitors.
摘要翻译： 本发明涉及选自式（I）的取代的恶唑衍生物的新化合物，其选择性调节，调节和/或抑制由涉及各种人和动物疾病的某些天然和/或突变型酪氨酸激酶介导的信号转导，例如 细胞增殖，代谢，过敏和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl和Flt-3抑制剂。
-
7.发明申请SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS 有权取代的氧唑衍生物及其作为酪氨酸激酶抑制剂的用途公开(公告)号：US20120108616A1
公开(公告)日：2012-05-03
申请号：US13343968
申请日：2012-01-05
IPC分类号： A61K31/422 , C07D413/14 , C07D263/48 , A61K31/4439 , A61K31/513 , A61P35/00 , A61P35/02 , A61P37/08 , A61P11/06 , A61P29/00 , A61P19/02 , A61P37/00 , A61P25/00 , A61P1/04 , C07D413/12
CPC分类号： C07D263/48 , C07D263/46 , C07D263/58 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Flt-3 inhibitors.
摘要翻译： 本发明涉及选自式（I）的取代的恶唑衍生物的新化合物，其选择性调节，调节和/或抑制由涉及各种人和动物疾病的某些天然和/或突变型酪氨酸激酶介导的信号转导，例如 细胞增殖，代谢，过敏和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl和Flt-3抑制剂。
-
公开(公告)号：US08110591B2
公开(公告)日：2012-02-07
申请号：US12654957
申请日：2010-01-11
申请人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
发明人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
IPC分类号： A61K31/421 , C07D263/30
CPC分类号： C07D263/48 , C07D413/04 , C07D413/14 , E21B33/038 , E21B43/121
摘要： The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
摘要翻译： 本发明涉及选自2-氨基咪唑的新化合物，其选择性调节，调节和/或抑制由涉及多种人和动物疾病的某些天然和/或突变型酪氨酸激酶介导的信号转导，例如细胞增殖，代谢， 过敏性和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl，FGFR3和/或Flt-3抑制剂。
-
公开(公告)号：US20070142390A1
公开(公告)日：2007-06-21
申请号：US10576267
申请日：2004-10-22
申请人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
发明人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
IPC分类号： A61K31/506 , A61K31/497 , A61K31/501 , A61K31/4709 , A61K31/4439 , A61K31/427 , A61K31/422 , C07D417/02 , C07D413/02
CPC分类号： C07D263/48 , C07D413/04 , C07D413/14 , E21B33/038 , E21B43/121
摘要： The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
摘要翻译： 本发明涉及选自式I的2-氨基咪唑的新化合物，其选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖的某些天然和/或突变型酪氨酸激酶介导的信号转导 ，代谢，过敏和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl，FGFR3和/或Flt-3抑制剂。
-
公开(公告)号：US07718676B2
公开(公告)日：2010-05-18
申请号：US10576267
申请日：2004-10-22
申请人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
发明人： Alain Moussy , Camille Wermuth , David Grierson , Abdellah Benjahad , Martine Croisy , Marco Ciufolini , Bruno Giethlen
IPC分类号： A61K31/44 , A61K31/422 , C07D263/30 , C07D413/04
CPC分类号： C07D263/48 , C07D413/04 , C07D413/14 , E21B33/038 , E21B43/121
摘要： The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
摘要翻译： 本发明涉及选自式I的2-氨基咪唑的新化合物，其选择性调节，调节和/或抑制由涉及多种人和动物疾病如细胞增殖的某些天然和/或突变型酪氨酸激酶介导的信号转导 ，代谢，过敏和退行性疾病。 更具体地说，这些化合物是有效和选择性的c-kit，bcr-abl，FGFR3和/或Flt-3抑制剂。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.038 秒)
